Skip to main content
Clinical Trials/NCT05099601
NCT05099601UnknownPhase 4

Topical Silymarin Versus Combined Topical Silymarin and Microneedling in Treatment of Melasma: Split Face Study

Assiut University0 sites30 target enrollmentStarted: May 1, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Enrollment
30
Primary Endpoint
compare between the efficacy of topical silymarin alone and its combination with microneedling in treatment of melasma.

Study Overview

Brief Summary

Melasma is an acquired pigmentary disorder, occurring most commonly on the face. It is more prevalent in females and darker skin types. Melasma is mainly a clinical diagnosis consisting of symmetric reticulated hypermelanosis in three predominant facial patterns: centrofacial, malar, and mandibular. Melasma, though benign, can be extremely psychologically distressing and has been shown to have a significant impact on quality of life, social and emotional wellbeing. Multiple factors are implicated in the pathogenesis of melasma; however, the definite underlying mechanisms are not yet completely established. Ultraviolet exposure is one of the leading etiological factors, besides genetic and hormonal factors.

Detailed Description

Many studies examined multiple treatment options for melasma, but none of them is completely satisfactory with recurrence in most cases.

Silymarin (SM) is a standardized extract from Silybum marianum seeds, is traditionally used as a hepatoprotective agent for its potent regenerative properties. Lately, SM is utilized in dermatological and cosmetic preparations for its antioxidant effect, anti-inflammatory and immunomodulatory properties.

Silibinin, the main component of silymarin, has been found to have antioxidant properties. It decreases the hazardous effects of solar ultraviolet radiation and significantly prevents melanin production in a dose-dependent manner without effect on cell viability.

Skin microneedling, or percutaneous collagen induction by needles, is a minimally invasive procedure that uses short fine needles to puncture the skin and stimulates fibroblast proliferation, release of growth factors and collagen production.

Long-term improvement of melasma after microneedling was reported , however, the exact mechanism that promotes skin lightening is not known.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age: 18-50 years old.
  • •Pattern of melasma: Bilateral symmetrical facial melasma of any pattern.
  • •Fitzpatrick skin phototypes: Types III, IV and V

Exclusion Criteria

  • •Pregnancy and lactation.
  • •Patients taking oral contraceptive pills, hormonal replacement therapy or treatment for chronic illness at the time of the study or during the past 6 months.
  • •Coexistance of diseases associated with hyperpigmentation such as Addison disease.
  • •Scarring and keloid tendency, active skin infections as active HSV.
  • •Previous history of post inflammatory hyperpigmentation.

Arms & Interventions

Silymarin alone versus silymarin and microneedling

Experimental

There will be one group of patients. Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.

Intervention: Silymarin (Combination Product)

Silymarin alone versus silymarin and microneedling

Experimental

There will be one group of patients. Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.

Intervention: Microneedling (Procedure)

Outcomes

Primary Outcomes

compare between the efficacy of topical silymarin alone and its combination with microneedling in treatment of melasma.

Time Frame: 3 months

Scoring of the patients according to modified Melasma Area and Severity Index (mMASI) score before and after treatment.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dina Abd El-nasser Attay

principal investigator

Assiut University

Similar Trials